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ABSTRACT
Background. Data on the efficacy and safety of methylphenidate in adults with attention deficit/
hyperactivity disorder (ADHD) are lacking in Europe. This study was undertaken to report on the
efficacy and safety of methylphenidate in an adult out-patient population with ADHD, and to
compare results with US data.
Method. A double-blind randomized cross-over trial comparing methylphenidate and placebo in
45 adults with ADHD with childhood onset was performed in a dose–titration design. Methyl-
phenidate was titrated from 0.5 mg/kg per day in week 1 up to 1.0 mg/kg per day in week 3.
Results. Response rates using methylphenidate varied between 38 and 51%, and using placebo
between 7 and 18% (p<0.05), depending on outcome measure used. Although the overall per-
centage of subjects having any side effect on both methylphenidate and placebo was rather high,
side effects on methylphenidate over and above those on placebo were few and mild.
Conclusions. Methylphenidate proves to be an effective and well tolerated treatment for symptoms
of ADHD in adults in the short term. Future research should study the long-term response and
clarify the impact of gender, co-morbidity, socio-economic status and IQ on response rates in adults
with ADHD.
INTRODUCTION
The recognition of attention-deficit/hyper-
activity disorder (ADHD) in adults is rapidly
growing in Europe. Many professionals have
noticed the results of follow-up studies in chil-
dren with ADHD, showing considerable per-
sistence of the disorder into adulthood
(Biederman et al. 2000; Barkley et al. 2002). The
prevalence of ADHD in adults based on epi-
demiological research has been estimated at
4.7% (Murphy & Barkley, 1996a). ADHD in
children as well as adults, is highly co-morbid
(Biederman et al. 1993; Kooij et al. 2001).
Recent research has shown that adult ADHD is
over-represented in populations with substance
use disorders, depression and anxiety disorders
(Alpert et al. 1996; Milberger et al. 1997; Fones
et al. 2000). This co-morbidity complicates di-
agnosis and treatment of ADHD in adults.
In the US, many articles and handbooks
about diagnosis and treatment of adult ADHD
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have been published. At the same time in
Europe, the diagnosis of ADHD in adults leads
to many diagnostic and treatment dilemmas
to solve. Although US data underscore the
descriptive, face, predictive and concurrent val-
idity of ADHD in adults (Spencer et al. 1998),
scepticism currently leads to under-diagnosis
and under-treatment of the adult form of this
disabling disorder in Europe. The diagnosis of
ADHD in adults as well as the treatment with
psychostimulants, have not yet reached the
same level of acceptance as in the USA.
Psychostimulants remain a viable first-choice
strategy for the pharmacotherapeutic treatment
of ADHD. Numerous controlled studies and
more than 40 years of clinical experience in
children have demonstrated the efficacy and
safety of psychostimulants for ADHD (Findling
et al. 1998). An overview of clinical research in
adults with ADHD between 1976 and 2001,
shows 5 open and 11 double-blind controlled
studies using stimulant medications, mostly
methylphenidate (Kooij et al. 2001; Prince et al.
2002). Except for one open study from our
group, controlled studies from Europe are
lacking. Response rates in controlled studies
range from 25% to 78%. Differences in re-
sponse rates appear to depend on variability in
diagnostic criteria, dose of stimulant prescribed,
rates of co-morbidity and response definitions.
Higher dosing of stimulants results in more
robust responses (Spencer et al. 2001). The
frequent co-morbidity accompanying ADHD
leads to diagnostic difficulties and treatment
dilemmas like the order of treatment of the dif-
ferent disorders and the impact of co-morbidity
on treatment outcome.
The few controlled studies using stimulants
in adult ADHD are all of US origin. There is
clearly a need for replication of these data in
Europe, to investigate similarities and differ-
ences in population and treatment outcome, in
order to further validate the diagnosis of
ADHD in adults. To our knowledge, this is
the first European study comparing methyl-
phenidate and placebo in a large sample of
adults diagnosed with ADHD. Mostly, clinical
trials fail to answer certain questions of clinical
practice due to inherent design features. One
of those questions is whether past or current
co-morbidity influences response rates of
methylphenidate compared to placebo. In this
cross-over trial we included those subjects re-
sembling patients in daily clinical practice.
METHOD
Subjects
Subjects were 45 out-patient adults with
ADHD. They were self-referred or referred by
other clinicians for assessment of ADHD to the
out-patient clinic of GGZ Delfland in Delft,
The Netherlands. The DSM-IV diagnosis of
childhood-onset and current ADHD was deter-
mined by a psychiatrist’s clinical evaluation sup-
plemented by the Dutch version of the DSM-IV
ADHD rating scale for current symptoms
(DuPaul et al. 1998). All ADHD types were
eligible. Subjects with co-morbid psychiatric
disorders were included, unless these disorders
required to be treated first or when treatment
with methylphenidate was contra-indicated.
We prospectively excluded subjects with clini-
cally significant medical conditions, abnormal
baseline laboratory values, a history of tic dis-
orders, mental retardation (IQ<75), organic
brain disorders, clinically unstable psychiatric
conditions (i.e. suicidal behaviours, psychosis,
mania, physical aggression, currently ongoing
substance abuse), current use of psychotropics,
prior use of methylphenidate or amphetamines,
as well as pregnant or nursing women. This
study was approved by the local Medical Ethical
Committee of the Reinier de Graaf Hospital in
Delft. All subjects completed a written informed
consent form before inclusion in the study.
Assessments
Prior to inclusion, patients underwent a stan-
dard clinical assessment consisting of a psy-
chiatric evaluation by one of two experienced
psychiatrists (S.K. or L.K.) using a semi-
structured diagnostic interview for ADHD and
co-morbid disorders, the Dutch version of struc-
tured diagnostic interviews for retrospective
diagnosis of ADHD and other disruptive dis-
orders of childhood, i.e. oppositional defiant
disorder (ODD) and conduct disorder (CD) as
well as antisocial personality disorder (ASP) in
adults (DIS-L, N, O, P; Robins et al. 1995), a
structured diagnostic interview for psychiatric
disorders, the Composite International Diag-
nostic Interview (CIDI, version 2.1, lifetime;
Robins et al. 1988), a semi-structured diagnostic
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interview for borderline and antisocial person-
ality disorders based on DSM-IV criteria, the
International Personality Disorder Examination
(IPDE; Loranger et al. 1994; Duijsens et al.
1999). Further assessments comprised a medical
history, a physical examination including blood
pressure, heart rate and weight measurement
as well as laboratory assessments (complete
blood cell count, liver, kidney, thyroid, glucose
function tests and electrocardiogram). Using
the CIDI we assessed anxiety disorders, mood
disorders, substance and alcohol use disorders,
and eating disorders. The CIDI generates diag-
nostic information about both past and current
disturbances.
For current ADHD-symptoms during the
last 6 months, we used a Dutch version of
the DSM-IV ADHD rating scale, based on the
18 DSM-IV items for ADHD (DuPaul et al.
1998). To facilitate reliability, five complex
items (item IA-a, IA-d, H-a, H-c, H-d) were re-
formulated into two single statements. Thus, the
questionnaire consisted of 23 items in total. The
wording of the items was slightly adjusted to
adults. Each item was to be rated by the phys-
ician on a scale from 0–3 (0=rarely or never;
1=sometimes; 2=often; 3=very often). In
rendering each item on the scale, the word
‘often’ was eliminated from the wording in the
original DSM-IV list, so that the frequency
could be chosen as an answer. Inattention and
hyperactive/impulsive items alternated in their
sequence listed on the scale. A symptom was
considered present if the answer given to the
item was ‘often’ or ‘very often’ (score 2 or 3).
This threshold reflects the wording in all of the
DSM-IV items as the frequency of occurrence to
be clinically relevant.
To be given a full diagnosis of adult ADHD,
subjects must have (1) met 6 of 9 DSM-IV cri-
teria of inattention and/or hyperactivity/im-
pulsivity for a diagnosis of ADHD in childhood
and at least 5 of 9 criteria in adulthood, (2) de-
scribed a chronic persisting course of ADHD
symptoms from childhood to adulthood, and (3)
endorsed a moderate to severe level of impair-
ment attributed to the ADHD symptoms. A
cut-off point of 5 of 9 criteria was set for adult
diagnosis of ADHD based on literature and
epidemiological data using the same DSM-IV
ADHD Rating Scale (Murphy & Barkley,
1996a ; Biederman et al. 2000).
In order to obtain information about lifetime
ADHD symptoms and impairment, the patient,
the partner and if available the parents were in-
terviewed. Information on school reports was
examined in order to build the diagnosis in
childhood.
To assess intellectual functioning, we ad-
ministered a short form (Block Design, Picture
Arrangement, Vocabulary and Arithmetic) of
the Dutch WAIS-III. The reliability of this short
form has not been established for the WAIS-III,
but for the WAIS-R the correlation with full
administration is 0.93 (McNemar, 1974).
Outcome measures
The outcomes of this study comprise three main
domains of symptoms: ADHD, depression and
anxiety. In addition we assessed impairment
and adverse events. To assess symptoms of
ADHD, we used the Dutch self-report-version
of the DSM-IV ADHD rating scale (DuPaul
et al. 1998) which has been shown to be sensitive
to drug effects in paediatric (Barkley, 1990) and
adult (Spencer et al. 1995) samples. For the
analyses the scores were first averaged over days
of the week and subsequently over all 23 items.
Severity of ADHD was assessed with the
Clinical Global Impression Scale for ADHD
(CGI-ADHD). The CGI has often been used in
psychopharmacology research and has been
shown to be drug sensitive (NIMH, 1985). We
used the global severity subscale of the CGI
(1 indicates not ill ; 7, extremely ill) in our
analyses.
For the assessment of depressive symptoms
we used the physician based 17-item Hamilton
Depression Scale (HAM-D) (cut-off clinical de-
pression>16). For anxiety we used the 14-item
physician based Hamilton Anxiety Scale
(HAM-A) (cut-off clinical anxiety >21). These
are widely used scales with established psycho-
metric properties (Hamilton, 1959, 1960).
We assessed functional impairment using the
Dutch version of the Sheehan Disability Scale
(SDS) ranging from 0 to10 in 3 domains (func-
tioning in work, social contacts/leisure time and
family (Sheehan et al. 1996). Functioning was
further assessed using the Global Assessment of
Functioning scale (GAF). The GAF scale
ranges from 10 to100 (APA, 1994).
In addition the subjects recorded adverse
events. We slightly modified the Side Effects
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Rating Scale from Barkley (Barkley & Murphy,
1998). The 14 items were rated from 0 to 3
(0 indicating ‘never’ ; 3 indicating ‘very often’).
All assessments were made at baseline and at the
end of the first and second treatment period,
except for the DSM-IV ADHD rating scale, the
CGI-ADHD and adverse events list, which were
administered weekly.
Outcome definitions
The primary outcome in this study was clinical
response defined as a decrease of at least 2
points on the investigator based CGI-ADHD
severity scale over the total treatment period (3
weeks), as well as a 30% symptom reduction or
more as measured by the self-reported DSM-IV
ADHD rating scale. Secondary outcomes were
the level of DSM-IV symptoms of ADHD, as
well as symptom levels of depression and anxi-
ety, global functioning (GAF), and impairment
(SDS). Safety measures were the occurrence of
adverse events (dichotomous), blood pressure,
weight, heart rate and number of adverse events
(all continuous).
Intervention
A randomized, placebo-controlled, double-
blind cross-over trial comparing methylpheni-
date with placebo was performed. There were
two 3-week treatment periods with 1 week of
washout in between. The order of treatment
(methylphenidate–placebo or placebo–methyl-
phenidate) was randomized by the pharmacist
using a computer generated list. Weekly supplies
of methylphenidate or placebo were dispensed
by the pharmacy in identically appearing tablets
of 10 mg. Medication was prescribed under
double-blind conditions in four or five times a
day dosing. Subjects used a device (Memos)
containing compartments for the tablets and a
timer in order to dose four or five times a day on
time. Dosing was adjusted to five times a day
when rebound occurred. Compliance was moni-
tored by electronic registration of the opening
of the device, at each visit to the pharmacy.
Compliance was defined as >80% of time
opening the device within 15 min after the
timer’s signal. Study medication was titrated up
from low to high doses to avoid exposure to
high initial doses of active medication and to
minimize side effects. Study treatment started
with 0.5 mg/kg per day by week 1, followed by
0.75 mg/kg per day by week 2, and up to 1.0 mg/
kg per day by week 3, unless adverse effects
emerged. This titration approach was chosen in
accordance with clinical practice and the trial of
Spencer et al. (1995). To control for possible
substance use, patients were asked two times
during the study to provide a urine sample.
Statistical analysis
The two randomized groups were first com-
pared with respect to baseline variables. Di-
chotomous outcomes were compared and tested
for statistical significance of treatment effects
using the McNemar test for paired proportions.
All continuous outcomes were statistically
tested for treatment effects using the paired
t test. Since dose titration took place over the
full 3-week treatment period, and to allow a
fully developed effect of methylphenidate to be
estimated, the results for weeks 3 (last week of
first period) and 7 (last week of second period)
were used for subsequent statistical analyses.
The level of significance (alpha) was 0.05 (two-
sided). We additionally explored the association
between response to methylphenidate (relative
to placebo) and age, gender and co-morbidity
at baseline in subgroup analyses. These associ-
ations were statistically tested using the x2 test,
or in case the expected number in a cell was
lower than five, Fisher’s exact test.
RESULTS
Study sample
After screening 108 subjects, 63 were not eligible















FIG. 1. CONSORT diagram (see text).
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we excluded 41 subjects due to clinically signifi-
cant medical conditions (4), abnormal baseline
laboratory values (1), clinically unstable psy-
chiatric conditions (7), current use of psycho-
tropics (11) and prior use of methylphenidate or
amphetamines (18). After diagnostic assess-
ment, 7 patients were ineligible due to currently
ongoing substance abuse (5), hypertension (1)
and severe depression that urgently required
treatment (1). Eligible and ineligible subjects
did not differ significantly in age or gender.
Forty-five subjects (41%) were randomized. 25
were treated with methylphenidate followed by
placebo, and 20 with placebo followed by me-
thylphenidate. Table 1 shows the demographic
and psychiatric characteristics of these subjects.
The subjects were out-patient adults, of whom
equal numbers of each gender were included (24
men and 21 women) between 20 and 56 years of
age (mean 39 years). All subjects satisfied diag-
nostic criteria for current ADHD with at least
5 of 9 symptoms of inattention and/or hyper-
activity/impulsivity, and a childhood onset with
at least 6 of 9 symptoms in one or both symptom
domains. Collateral information was available
of 41 family members (34 parents and 7 siblings)
and 28 partners. All family members and
partners confirmed the diagnosis to a certain
extent. The extent varied between ‘very likely ’
(25 partners and 26 family members), ‘ likely ’
(3 partners and 7 family members) and ‘poss-
ible ’ (8 family members).
According to the DSM-IV ADHD rating
scale for current symptoms, 43 patients met cri-
teria for ADHD, combined type and 2 for
ADHD, hyperactive/impulsive type. All sub-
jects completed the trial. One subject completed
the last week of the study 1 week later for
logistic reasons. One subject used morphine in
the fifth week, as measured with urine control
and confirmed by urinary analysis. Data of both
Table 1. Demographic and clinical
characteristics
Characteristic Value
Number of subjects 45
Male, n (%) 24 (53.3)
Mean age (range) 39.1 (20–56)
Marital status
Married/relationship, n (%) 28 (62.2)
Single/divorced/living with parents, n (%) 17 (37.8)
School failure, n (%) 34 (76)
Repeated grade, n (%) 14 (31)
Special class, n (%) 8 (18)
Tutoring, n (%) 12 (27)
Educational level
Lower educational level, n (%) 26 (58)
High school, n (%) 14 (31)
University, n (%) 5 (11)
Cognitive testing
Full scale IQ, mean (S.D. ; range) 101 (18; 76–142)
Working, n (%) 31 (69)
Social security/sickness benefit, n (%) 13 (29)
Impairment
SDS, mean (S.D.) 7.6 (1.1)
Current GAF, mean (S.D.) 57 (6.1)
Any co-morbid axis I disorder, n (%) 35 (78)
Multiple (o2) disorders, n (%) 23 (66)
Total number of axis I disorders (mean) 104 (3.0)
Past, n 81
Current (f6 months), n 23
Any mood disorder, n (%) 23 (66)
Past, n (%) 17 (49)
Current (f6 months), n (%) 6 (17)
Multiple mood disorders (o2), n (%) 6 (17)
Mood disorders, n 28
Major depression, n 15
Dysthymia, n 7
Bipolar I disorder, n 6
HAM-D baseline, mean (S.D.) 8.0 (5.8)
HAM-D baselineo6, n (%) 4 (9)
Any anxiety disorder, n (%) 22 (63)
Past, n (%) 10 (29)
Current (f6 months), n (%) 12 (34)
Multiple (o2) anxiety disorders, n (%) 8 (23)
Anxiety disorders, n 34
Obsessive-compulsive disorder, n 3
Specific phobia, n 12
Social phobia, n 9
Panic disorder, n 3
Agoraphobia, n 3
Generalized anxiety disorder, n 2
Post-traumatic stress disorder, n 2
HAM-A baseline, mean (S.D.) 7.8 (6.0)
HAM-Ao21, n (%) 2 (4)
Any substance use disorder (SUD), n (%) 18 (51)
Past, n (%) 15 (43)
Current (f6 months), n (%) 3 (9)
Multiple (o2) SUDs, n (%) 9 (26)
SUDs, n 37
Alcohol abuse, n 11
Alcohol dependence, n 3
Cannabis abuse, n 2
Cannabis dependence, n 2
Nicotine dependence, n 11
Nicotine withdrawal, n 6
Other SUD, n 1
Bulimia nervosa, n (%) 3 (9)
Past, n (%) 1 (3)




personality disorder, n (%)
15 (33)
Prior treatment, n (%) 39 (87)
Age first treatment (n=41), mean (range) 18.3 (2–43)
2–20 years, n (%) 25 (61)
>21 years, n (%) 16 (39)
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subjects have been included in the analyses
according to the intention to treat principle.
After randomization, the two treatment order
groups (methylphenidate–placebo, and placebo–
methylphenidate) did not differ on any of the
demographic and clinical characteristics as de-
scribed in Table 1.
Average daily doses of methylphenidate
and placebo by the end of week 1 were 0.5 mg/
kg (0.31–0.55 mg/kg) and 0.5 mg/kg (0.45–
0.55 mg/kg) respectively ; by week 2: 0.75 mg/kg
(0.31–0.82 mg/kg) and 0.76 mg/kg (0.69–0.82
mg/kg); by week 3: 0.91 mg/kg (0.54–1.04 mg/
kg) and 0.98 mg/kg (0.71–1.04). 16/45 subjects
using methylphenidate preferred the five in-
stead of four times a day dosing in the third
week v. 6/45 subjects using placebo.
According to the combined DSM-IV ADHD
rating scale and CGI-severity outcome measure,
7% responded to placebo v. 38% to methyl-
phenidate (Fig. 2). This difference being the
primary measure of efficacy was statistically
significant (p=0.003). These figures were 0 and
16 in week 1, and 7 and 29 in week 2, respect-
ively.
If response was based solely on the DSM-IV
ADHD rating scale, i.e. based on the subject’s
rating only, these percentages at endpoint were
somewhat higher: 13% and 42% respectively
(p=0.011). In the first week they were 4% and
20%, in the second week 11% and 31% re-
spectively. In terms of CGI-severity, i.e. based
on investigator’s assessment, 18% responded to
placebo at endpoint, and 51% to methylpheni-
date (p=0.011). In the first week these percent-
ages were 4% and 24%, in the second week
16% and 44% respectively.
In Table 2 mean symptom levels per week for
both groups separately are shown according to
outcome measure. After 3 weeks of methylphe-
nidate a substantially lower symptom level as
measured by both the DSM-IV ADHD rating
scale as well as the CGI-severity was observed
than during placebo treatment. On average,
methylphenidate use was associated with a 0.19
lower DSM-IV ADHD rating scale score
(p=0.064) and a 0.72 lower score on the CGI-
severity score (p=0.026) compared to placebo.
Compliance data were available for 41 sub-
jects : 13 were non-compliant v. 28 compliant
(compliance=taking medication >80% of
time within 15 min after the timer’s signal). Re-
sponse rates differed between compliant and
non-compliant subjects : 43% responded in
the compliant (12/28) v. 23% (3/13) in the non-
compliant group (Fisher’s exact test, p=0.31).
This trend reached no significance due to small
sample sizes.
Table 2. Raw scores of primary outcome measures (mean, S.D.), by treatment-order group
(Mph–Plac/Plac–Mph) and week of treatment
Outcome measure Wk 1 Wk 2 Wk 3 Wk 5 Wk 6 Wk 7
DSM-IV ADHD Rating Scale*
Mph–Plac 1.57 (0.55) 1.44 (0.66) 1.37 (0.65) 1.47 (0.55) 1.48 (0.59) 1.45 (0.59)
Plac–Mph 1.62 (0.56) 1.54 (0.62) 1.55 (0.56) 1.42 (0.56) 1.42 (0.59) 1.24 (0.74)
CGI-Severity ADHD#
Mph–Plac 4.96 (1.46) 4.40 (1.35) 4.36 (1.47) 5.48 (0.96) 5.32 (1.18) 5.40 (1.50)
Plac–Mph 5.05 (0.76) 4.95 (1.19) 4.80 (1.47) 4.95 (1.47) 4.80 (1.70) 4.40 (1.70)




























FIG. 2. Summary of response (%) to methylphenidate (&) and
placebo (%) in the cross-over analysis at the end of the treatment
period, according to three different definitions of response (see text) ;
p values from McNemar test.
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Compared to placebo, 0.93 lower score on
the SDS was observed after methylphenidate
treatment (p=0.029). Better functioning on
methylphenidate was also apparent from a 2.5
higher GAF score, but this was not statistically
significant (p=0.104). Methylphenidate was
associated with higher symptom levels of de-
pression and anxiety than placebo, as was
apparent from higher HAM-D and HAM-A
scores : 2.4 (p=0.002) and 2.9 (p=0.002) points,
respectively. When defined as a HAM-D >16,
11% (n=5) had depression after methylpheni-
date compared to 9% (n=4) after placebo.
When defined as a HAM-A >21, 7% (n=3)
had anxiety after methylphenidate compared to
4% (n=2) after placebo.
Exploratory analyses revealed that the clinical
response to methylphenidate was not clearly
affected by gender, age, lifetime or current
(within the last 6 months) co-morbidity, severity
of anxiety and depression or intelligence (details
can be obtained from the first author on re-
quest).
Adverse effects
While treated with methylphenidate 82% of the
subjects reported any adverse effect on the Side
Effects Rating Scale, v. 69% during treatment
with placebo (p=0.11). The mean number of
adverse effects was 0.9 higher during methyl-
phenidate than during placebo (p=0.004). The
only adverse effect that occurred significantly
more often using methylphenidate than using
placebo, was loss of appetite (22% v. 4%;
p=0.039). Sleeping problems (33% v. 22%;
p=0.27), headache (16% v. 4%; p=0.18),
tachycardia (9% v. 2%; p=0.25), dizziness
(16% v. 7%; p=0.34), abdominal complaints
(13% v. 4%; p=0.22), dry mouth (24% v. 7%;
p=0.06) and tics (7% v. 2%; p=0.5) were
somewhat more prevalent during methylpheni-
date than during placebo treatment, but these
differences were not statistically significant. The
rate of other adverse effects was similar for
methylphenidate and placebo. Adverse effects
were no reason for drop-out.However, 8 patients
(18%) lowered their dose due to adverse effects
using methylphenidate, compared to none using
placebo. One patient lowered the dose due
to headache after the first week, and 7 due to
nervousness/irritability before starting the
highest dose in the third week.
Further, compared to placebo, the systolic
blood pressure was 0.13 mmHg higher after
methylphenidate but this was not statistically
significant (p=0.954). The diastolic blood
pressure remained virtually unchanged. Mean
heart rate was 4.8 beats/min higher (p=0.002)
and mean body weight was 1.7 kg lower (p<




This is the first European randomized double-
blind study comparing methylphenidate to
placebo in a large sample of adults with ADHD.
Indeed, ADHD in adults can be identified and
reliably diagnosed using the same diagnostic
procedures as in the USA, using collateral in-
formation about childhood onset of symptoms
and current functioning.
We demonstrated that short-acting methyl-
phenidate with an average daily dose of 0.9 mg/
kg per day, is an effective and well tolerated
treatment in the short term. Response started at
the lowest dose in the first week and proved
more robust using higher doses. This is in
accordance to other paediatric and adult studies
using a stepwise increase in dose (Rapport et al.
1987; Spencer et al. 1995). In addition, short-
term use of methylphenidate was associated
with improved functioning in daily work, social
activities and family life. Placebo response
was low. This is also in accordance with other
studies using methylphenidate in children and
adults with ADHD (Spencer et al. 1996).
No marked effect of gender, age, lifetime or
current (within the last 6 months) co-morbidity,
intelligence or severity of anxiety and depression
on the effectiveness of methylphenidate could be
found. However, definite conclusions cannot be
drawn as to the influence of these factors due to
small sample sizes, and therefore limited stat-
istical power.
Although methylphenidate as compared to
placebo slightly and significantly increased
the level of depressive and anxiety symptoms,
the clinical significance of these findings was
unclear. Above, no serious symptoms of anxiety
or depression emerged in the short-term that
led to adjust clinical management of any of
the subjects. Future research should clarify the
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course of depressive and anxiety symptoms
during treatment with methylphenidate in the
long-term.
The mean higher heart rate and mean lower
body weight during methylphenidate treatment
were not clinically significant and no subject re-
quired alteration of the dose as a consequence.
These changes are in accordance with the
literature (Spencer et al. 1995). Although the
overall percentage of subjects having any side
effect on both methylphenidate and placebo was
rather high, side effects on methylphenidate
over and above those on placebo were few and
mild. Only loss of appetite happened statisti-
cally significantly more frequently when com-
paring methylphenidate with placebo. Adverse
effects were no reason for dropout. Most
patients were able to tolerate the highest average
daily dose of 0.9 mg/kg per day. The frequency
of dose reduction and the frequency and the
kind of adverse effects are in accordance with
the literature in controlled studies in children
and adults using methylphenidate (Barkley et al.
1990; Spencer et al. 1995).
Comparison with US studies
In the eight controlled trials in adults with
ADHD using methylphenidate response rates
between 25% and 78% have been reported.
Discrepancies in response rates have been
attributed to differences in ascertainment, sam-
ple characteristics with varying levels of co-
morbidity, diagnostic methods and daily doses.
Of all studies performed, we used the largest
sample (n=45 v. n=8–37, mean 25). Our
response rates, varying between 38% and 51%
depending on outcome measure used, are in
accordance to other studies. Results of these
studies, however, are difficult to compare, as
no information about ascertainment and co-
morbidity was provided, diagnostic criteria
and outcome measures were not well defined
and lower doses of methylphenidate were used
(0.4–0.7 mg/kg per day) (Prince & Wilens,
2002). The most similar US study from Spencer
et al. (1995), used the same double-blind cross-
over design, outcome measures and outcome
definitions, and the same dose titration to
0.9 mg/kg per day. The reported response rate
was 78%. A difference between the two studies
is the use of only investigator-based outcome
measures (Spencer), whereas we used both
investigator-based and subject-based ratings
(CGI-Severity respectively DSM-IV ADHD
rating scale). The investigator-based response
rate was slightly higher than that based on the
subjects’ ratings only; the combined outcome
measure showing the lowest response rate. This
use of combined investigator and subject ratings
might be partly responsible for the differences in
outcome.
In addition, possible explanations for our
lower response rate are the following differ-
ences : a different ascertainment and referral
pattern (psychiatric outpatients v. high intellec-
tual and socio-economical functioning academic
underachievers), we excluded less subjects
(enrolment 41% v. 29%), and included more
lifetime co-morbid disorders (mean 3.0 v. 2.6),
and more cluster B personality disorders (33%
v. 13% its predecessor, conduct disorder).
Almost every subject had a history of prior
psychiatric of psychological treatment (87%)
compared to none in the Spencer study,
and 61% of those subjects started treatment
before the age of 20 years. In addition,
our population had a higher history of school
failure (76% v. 43%) and lower mean IQ (101 v.
114) leading conceivably to a lower educational
(this study 58%) and socio-economical level
(Spencer’s study: 74% highest socio-economic
strata).
The conclusion could be that our more psy-
chiatrically disturbed outpatient population,
being more impaired on various measures,
shows lower response rates than a more intel-
lectual population being referred for under-
achievement. The population we included in this
trial seems more representative of the patients
seen in daily clinical practice, where many
children and adults with ADHD suffer from two
or more co-morbid disorders (Biederman et al.
1993; Murphy & Barkley, 1996b ; Kooij et al.
2001), and adults with ADHD often have
co-morbid personality disorders (Mannuzza
et al. 1993). In addition, adults with ADHD
have a mean duration of 12.5 years previous
psychological or psychiatric treatment (Kooij
et al. 2001) and lower educational levels and
socio-economic status (SES) due to under-
achievement (Seidman et al. 1998). Possibly,
the use of subject-based ratings leads to lower
response rates than the use of investigator’s
ratings. This could be attributable to the
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subjects’ difficulties in reflecting on their own
behaviour, leading to under-reporting.
The high percentage of lifetime co-morbid
substance use disorders (51%) is characteristic
for the adult population. An important research
question is whether ongoing treatment with
methylphenidate can reduce substance abuse
in this population. In children with ADHD,
treatment with methylphenidate proved to re-
duce the risk of substance abuse to a normal
level ; a recent review in adults with ADHD and
substance abuse indicated the same conclusion
(Wilens et al. 2003).
Recently, new stimulant preparations for
ADHD have or will soon come to the market in
the USA, all using long-acting delivery systems.
These long-acting, once daily psychostimulant
medications are likely to improve the adherence
to prescribed regimens and the level of care for
adults with ADHD. In future research using
larger samples and a long-term design, the
impact of gender, IQ, history of prior treatment,
and co-morbidity on response rates using (long-
acting) methylphenidate and other medications
should be further clarified.
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